西格列汀联合二甲双胍治疗腹型肥胖2型糖尿病的效果及安全性  

Efficacy and safety of sigliptin combined with metformin in the treatment of abdominal obesity type 2 diabetes meliitus

作　　者：邹慧[1] 邱伟[1] 李欣[1] Zou Hui;Qiu Wei;Li Xin(Department of Endocrinology,Xinxiartg First People's Hospital,Xinxiang 453000,China)

机构地区：[1]河南省新乡市第一人民医院内分泌科,453000

出　　处：《中国实用医刊》2019年第21期114-117,共4页Chinese Journal of Practical Medicine

摘　　要：目的分析二甲双胍联合西格列汀治疗腹型肥胖2型糖尿病的效果及安全性.方法选取2018年1月至2019年1月新乡市第一人民医院收治的92例腹型肥胖2型糖尿病患者,根据随机数字表法分为观察组和对照组,每组46例.对照组在常规治疗基础上加用二甲双胍,观察组在常规治疗基础上加用二甲双胍和西格列汀,比较两组治疗前后血糖、血脂指标变化情况及不良反应发生情况.结果治疗前,两组血糖相关指标检测值比较差异未见统计学意义(P>0.05);治疗后,观察组空腹血糖、糖化血红蛋白、餐后2 h血糖水平降低幅度优于对照组(P<0.05).治疗前,两组血脂指标及体质指数(BMI)比较差异未见统计学意义(P>0.05);治疗后,两组总胆固醇、三酰甘油、低密度脂蛋白胆固醇、BMI水平较治疗前下降,且观察组下降幅度优于对照组(P<0.05).观察组因药物所致不良反应发生率为13.04%(6/46)、对照组为10.87%(5/46),两组比较差异未见统计学意义(P>0.05).结论二甲双胍联合西格列汀治疗腹型肥胖2型糖尿病的有效性及安全性均较优.Objective To analyze the efficacy and safety of combined use of metformin and sitagliptin in the treatment of abdominal obesity type 2 diabetes meliitus.Methods Ninety-two abdominal obesity type 2 diabetes melitus patients admitted to Xinxiang First People's Hospital from Januaiy 2018 to Januaiy 2019 were selected,and they were divided into observation group and control group by the random number table method,with 46 cases in each group.The control group was treated with metformin on the basis of routine treatment,while the observation group was treated with metformin and ceglistine on the basis of routine treatment.The changes of blood glucose and blood lipids before and after treatment,and the occurrence of adverse reactions were compared between the two groups.Results Before treatment,there was no significant difference in blood glucose related indicators between the two groups(P〉0.05).After treatment,the levels of fasting blood glucose,glycosylated hemoglobin and postprandial 2-hour blood glucose(2 h PG)in the observation group were significantly lower than those in the control group(P<0.05).Before treatment,there was no significant difference in blood lipid index or body mass index(BMI)between the two groups(P>0.05).In comparison to preoperative indexes the levels of total cholesterol,triglyceride,low density lipoprotein cholesterol and BMI in the two groups decreased after treatment,and the decrease in the observation group was better than that in the control group(P<0.05).The incidence of adverse reactions was 13.04%(6/46)in the observation group and 10.87%(5/46)in the control group,but there was no significant difference between the two groups(P>0.05).Conclusions The efficacy and safety of metformin and sitagliptin in patients with abdominal obesity type 2 diabetes meliitus are superior.

关 键 词：2型糖尿病 腹型肥胖 二甲双胍 西格列汀 

分 类 号：R587.1[医药卫生—内分泌]